IDH2 and glioblastoma: For instance, fewer than 30% of IDH-wild-type glioblastomas show TP53 mutations; however, their acquisition occurs later in tumor progression, their behavior is more aggressive, and their grade is higher [2,6,7], thus suggesting a different and critical role of TP53 mutations in IMA.